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n ACE in the Hole
lternative Pathways of the
enin Angiotensin System and Their
otential Role in Cardiac Remodeling*
arry Greenberg, MD, FACC
an Diego, California
here is compelling evidence that the renin angiotensin
ystem (RAS) plays a major role both in maintaining
ardiovascular homeostasis and the pathogenesis of cardio-
ascular diseases ranging from hypertension to heart failure.
n the classical RAS (depicted in Fig. 1), angiotensinogen
eleased into the circulation from the liver is enzymatically
egraded by renin that originated in the kidney to generate
he inactive precursor molecule angiotensin (Ang I). When
his decapeptide comes into contact with angiotensin-
onverting enzyme (ACE) at the endothelial surface of
lood vessels, the 2 terminal amino acids are cleaved from
he carboxy terminus, giving rise to Ang II, the main
ffector molecule of the RAS. Through interactions with
pecific receptors, and in particular its type 1 or AT1
eceptor, Ang II stimulates a wide variety of signaling
athways in the heart, blood vessels, kidneys, and brain to
nitiate most of the physiologic and pathophysiologic effects
hat have been attributed to the RAS.
See page 750
During the past 2 decades we have learned, however, that
he RAS is considerably more complex than the system just
escribed. Many cells are able to generate components of
he RAS, with the result being the capacity for local Ang II
roduction in organs throughout the body (1). A cardiac
AS has been detected, although in this case, renin activity
ay be extracted from the blood rather than produced
ocally in the heart itself. Alternative pathways for convert-
ng Ang I to II that exist in cardiac tissue further complicate
he picture. In addition, Ang receptors other than the AT1
eceptor have been identified, though their exact role re-
ains controversial.
The importance of the RAS in heart failure is well
stablished. Plasma renin activity is increased during the
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or thep
merican College of Cardiology.
From the University of California, San Diego, California.ourse of the disease (often in association with the presence
f symptoms or in response to treatment with diuretics) (2),
nd the systemic effects of Ang II, which include peripheral
rterial vasoconstriction and salt and water retention, con-
ribute to the heart failure phenotype. Maladaptive cardiac
emodeling has been recognized as the underlying process
hat leads to the progression of heart failure. Remodeling is
nitiated in response to injury to the heart, such as what
ccurs after a myocardial infarction (MI), and it involves a
omplex series of events that result in eccentric hypertrophy
f the left ventricle, with increases in both volume and mass,
ncreased sphericity of the chamber, diffuse myocardial
brosis, and the development of secondary mitral insuffi-
iency. These alterations in the gross morphology of the
eart, along with changes in cardiomyocyte and cardiac
broblast structure and function, cause progressive deterio-
ation in cardiac performance and ultimately to the devel-
pment of heart failure. The local cardiac RAS has been
hown to play a particularly important role in this process.
ngiotensin II production is increased within the remod-
ling heart (3) and increased density of the AT1 receptor on
ardiac cells further enhances the progrowth and fibrotic
ffects of the peptide (4). Studies performed in experimen-
al animal models and in human patients have shown that
trategies designed to block either the production or
ffects of Ang II inhibit maladaptive cardiac remodeling
5) and significantly reduce heart failure morbidity and
ortality (6).
The discovery of a homolog of ACE that has been
ermed ACE2 raises the exciting possibility that addi-
ional alternative pathways of the RAS might be involved
n the regulation of this system (7). Both ACE and
CE2 are type 1 ectoenzymes, which are anchored to the
ell membrane with their enzymatic domains residing
xterior to the cell surface. The activity of ACE2 is
mpervious to classical ACE inhibitors, although there is
vidence that these agents, as well as angiotensin receptor
lockers, increase ACE2 gene expression (8). Although
CE2 can act on a variety of factors (some of which are
oted in Fig. 1), its preferred substrate appears to be Ang
I, from which it cleaves the terminal amino acid to form
ng(1-7). The cellular effects of Ang(1-7) are mediated
y a receptor (or receptors) that is unique from the AT1
r AT2 receptor subtypes, and there is evidence that
any of these involve the G-protein– coupled 7 trans-
embrane domain Mas receptor (9). In cardiac myocytes,
ng II has been reported to have antihypertrophic effects
10), whereas in cardiac fibroblasts, the heptapeptide
nhibits collagen production, expression of “secondary”
rowth factor genes, and Ang II-stimulated cardiomyo-
yte hypertrophy that is dependent on factors released
rom cardiac fibroblasts (11).
Thus, by reducing concentrations of Ang II, which hasrogrowth and profibrotic effects, and increasing the gen-
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Editorial Comment August 26, 2008:755–7ration of Ang(1-7), ACE2 could have a beneficial role in
he failing heart by restraining or even reversing cardiac
emodeling. In support of this possibility is evidence that
eletion of the ACE2 gene leads to the development of
eart failure and that this effect can be inhibited by further
eletion of the ACE gene (12). Moreover, in experimental
odels Ang(1-7) has been reported to inhibit Ang II-
timulated cardiac remodeling (13) and to improve cardiac
unction in the post-MI remodeling heart (14).
The role of ACE2 in the human heart remains uncertain.
ecent evidence that ACE2 gene expression is increased
n both the post-MI and the failing human heart (15,16)
upports the possibility that the counter-regulatory ef-
ects of this enzyme may be enhanced in certain patho-
hysiologic settings. In this issue of the Journal, Epelman
t al. (17) report that, in a cohort of heart failure patients,
CE2 activity in plasma is increased and that these
hanges were not dependent on etiology (e.g., ischemic
Figure 1 A Novel Pathway of the RAS Involving ACE2
Classical and alternative pathways of the renin angiotensin system. Angioten-
sin-converting enzyme (ACE)2 activity alters the ratio between Angiotensin (Ang)
II and Ang(1-7) by cleaving the terminal amino acid from either Ang I or Ang II.
As opposed to Ang II, which has pre-growth and vasoconstricting properties,
Ang(1-7) has been shown to have antigrowth and vasodilatory properties. RAS
 renin angiotensin system. Figure illustration by Rob Flewell.s. nonischemic). Moreover, ACE2 levels appear to
bncrease in a step-wise fashion as the severity of heart
ailure progresses, as indicated by both New York Heart
ssociation functional class status and by levels of B-type
atriuretic peptide. These exciting new findings demon-
trating that plasma ACE2 activity is increased in heart
ailure patients suggest that the production and/or pro-
essing of this enzyme are modified as part of the disease
rocess, and they raise the intriguing possibility that
hanges in ACE2 activity could be involved in altering
he ratio between Ang II and Ang(1-7) and their result-
nt effects on cardiac cell structure and function.
Although the observations of Epelman et al. (17) are a
otentially important step forward, the findings should be
laced in the context of what is known about ACE2 and
ow it is processed. The activity of ACE2 was measured in
lasma, and there is no indication from which tissue the
reater level of enzyme activity might have originated, nor is
t known which step in the processing of ACE2 might have
een altered. It is possible that the changes observed in these
atients could have been the result of increases in either
CE2 gene expression, translation into protein, intracellu-
ar processing and delivery of the mature enzyme to the cell
urface, and/or its subsequent cleavage from the cell mem-
rane. Decreased breakdown of the enzyme in the circula-
ion could also be involved. The possibility that changes in
CE2 activity in the plasma are due to increased cleavage is
articularly intriguing, however, because the activity of
umor necrosis factor-–converting enzyme (i.e., TACE),
n enzyme that has been identified as playing a role in
CE2 cleavage (18), is increased in the setting of heart
ailure (19). If that does turn out to be case, it is possible
hat the increases in plasma ACE2 level could indicate that
he potentially protective regulatory activity of the enzyme
ithin the myocardium has been reduced and balance
etween factors promoting and inhibiting remodeling has
een shifted in an unfavorable direction.
There is clearly much more work to be done in this area.
he value of the report by Epelman et al. (17) is that it now
urns our attention to the possibility that ACE2 may indeed
e a “player” in the complex series of events that are
esponsible for the development and progression of heart
ailure. As studies looking at the effects of regulating ACE2
ctivity in the remodeling heart progress over time, we may
ell find that we have been presented with a novel thera-
eutic target for the treatment of heart failure. If so, having
n ACE (or more correctly an ACE2) in the hole may be as
elcome to clinicians as having the proverbial “ace in the
ole” is to the individual sitting at the poker table.
eprint requests and correspondence: Dr. Barry Greenberg,
rofessor of Medicine, Director, Advanced Heart Failure Treat-
ent Program, University of California, San Diego, 200 West
rbor Street, San Diego, California 92103-8411. E-mail:
greenberg@ucsd.edu.
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